Celularity Inc. 8-K Summary
Business Context and Reporting Period
Celularity Inc. (CELU) filed a Current Report on Form 8-K on October 9, 2024, regarding a material definitive agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
This filing reports a specific asset acquisition rather than periodic financial results. The aggregate consideration for the acquisition is $5,500,000, structured as follows:
- Upfront Cash Payment: $1,000,000
- Milestone Payments: Up to $4,000,000 in monthly payments
- Credit Applied: $500,000 credit for a previous payment made under a letter of intent dated August 16, 2024
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Agreement Terms
On October 9, 2024, Celularity acquired Sequence Life Science, Inc.'s Rebound full thickness placental-derived allograft matrix product and related assets. Key terms include:
- Milestone Calculation: Monthly payments equal to 20% of net sales collected by Celularity from customers during the preceding calendar month, commencing the first full month after closing.
- Supply Agreement: An exclusive supply agreement was executed for a minimum period of six months.
- Manufacturing: Celularity retains the right to manufacture the product internally and intends to commence technology transfer as soon as practicable.
Outlook, Risks, and Management Commentary
Management intends to file the full Asset Purchase Agreement as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2024. A press release regarding the agreement was issued on October 16, 2024. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard qualification that the description is subject to the full agreement text.
Investor Verification Checklist
- Verify the exact terms of the 20% net sales milestone calculation in the full Asset Purchase Agreement.
- Confirm the timeline for the technology transfer and internal manufacturing capability.
- Review the press release dated October 16, 2024, for additional strategic context.
- Monitor future filings for the impact of the $1,000,000 upfront cash outflow on liquidity.